The NPKUA Psychosocial Committee — made up of dedicated mental health practitioners — is excited to share this quarterly update with our PKU community. In each edition, they will explore topics related to mental health, wellness and living with PKU, offering insights, tips and resources to support emotional well-being. Their goal is to foster connection, understanding and resilience within the PKU community, and they hope you find inspiration and encouragement in these pages.
Starting a New Treatment for PKU: Navigating Hope, Uncertainty and Change
By Eugene Lubliner, Psy.D., BCBA, LBA
Given the expanding list of treatment options available for people with PKU, it is truly an incredible time to be caring for someone with this metabolic condition. Advances in research have led to therapies that were unimaginable just a generation ago. However, one of the lesser-discussed aspects of these medical advances is the emotional and psychological impact that can accompany changes in treatment regimens.
For many families and individuals living with PKU, treatment has long meant structure, vigilance, and routine. Everyone in the community is familiar with carefully measured foods; regular bloodwork; formula schedules; and planning ahead for school, work, travel, and social events. Over time, these routines become more than medical task. They become part of daily life and, often, part of our identity.
So, when a new treatment option becomes available—whether it’s sapropterin, sepiapterin, pegvaliase, or another emerging therapy—it can bring both excitement and uncertainty. Starting something new in PKU care is rarely just a medical shift. It is an emotional and psychological transition as well. And with continued advances on the horizon, more and more patients and their families will encounter these moments of change.
It is completely normal to feel hopeful and anxious at the same time.
Why Change Can Feel So Big
PKU treatment has evolved significantly over the past several decades. Clinical guidelines continue to develop as research expands our understanding of long-term metabolic control and quality of life (van Wegberg et al., 2017). New therapies offer the possibility of improved phenylalanine (Phe) levels, greater dietary flexibility, and, in some cases, reduced cognitive and emotional burden due to diet liberalization.
However, change can feel destabilizing, especially when families have spent years being told that strict, consistent management is essential. Many parents and patients have internalized powerful messages about safety, risk, and lifelong vigilance. When new options are introduced, it can raise understandable questions about trust, safety, and outcomes. Change challenges routine, and routine often feels like security.
Not Everyone Responds to New Treatments
Before beginning a new therapy, it is important to understand that responses vary. Some individuals experience significant reductions in Phe levels with new treatments. Others may have partial responses, and some may not respond at all (Burton et al., 2015; Longo et al., 2019). This variability is biological, not personal.
If a new treatment does not produce the desired metabolic response, your care team may recommend returning to a previous regimen, such as stricter dietary management. While medically appropriate, this can feel emotionally difficult. Disappointment, frustration, or even self-doubt are common reactions.
Trying a new therapy is not a gamble, it is a carefully monitored process. Even if the outcome is a return to a previous plan, the experience provides valuable information that helps guide long-term care. In PKU management, adjustment is part of responsible decision-making, not a setback.
A Personal Reflection
Recently, my family experienced this firsthand. Our 10-year-old daughter, who has classic PKU, trialed a new medication. We approached it with cautious optimism. We reorganized routines, learned new dosing schedules, coordinated additional labs, and built new daily habits around delivering the medication. Like many families, we allowed ourselves to hope this might make things a little easier for her.
After giving it a fair trial, her numbers looked essentially the same as they had on her previous treatment. On paper, that might seem neutral. Stable is good. But emotionally, it was more complicated. There was frustration in having invested the time and energy to adapt to something new. There was the mental load of changing routines. There was the quiet disappointment of realizing that, biologically, her body simply did not respond differently.
Ultimately, we made the decision, together with her care team, to return to her previous medication. That decision wasn’t dramatic. It wasn’t a failure. It was data. It was information about how her unique body responds. But it was still hard.
What this experience reinforced for us is something important: trying a new treatment is not just a medical adjustment. It is a family adjustment. It requires flexibility, emotional energy, and resilience. And sometimes, the bravest outcome is acknowledging that the old regimen remains the best fit for now.
When Treatment Works: The Stress of Diet Liberalization
When a new treatment lowers Phe levels successfully, dietary liberalization may become possible. For many, this represents long-awaited flexibility—more food choices, fewer restrictions, and greater ease in social situations. At the same time, liberalizing diet after years of strict control can feel surprisingly stressful.
Parents who have carefully monitored every gram of protein may feel anxious loosening that structure. Individuals who have long avoided certain foods may experience unexpected guilt when reintroducing them. Some worry about “going too far” or losing control. Others find that the clear boundaries of the traditional PKU diet provided a sense of stability that now feels less defined.
Relief and anxiety often coexist.
Clinical research and patient reports highlight that PKU affects not only metabolic functioning but also emotional well-being and identity (Bilder et al., 2016; Ford et al., 2018). Dietary changes can challenge long-standing beliefs about safety and responsibility, and adjustment to this “new normal” may take time.
The Psychological Load of Treatment Transitions
Managing PKU already requires significant cognitive and emotional effort. Adding a new medication, adjusting diet, increasing lab monitoring, or tracking side effects temporarily increases that load.
During this period, it is common to notice heightened anxiety before lab draws, increased focus on numbers, sleep disruption, irritability, or decision fatigue. Because metabolic control is closely linked with cognitive and emotional outcomes (Bilder et al., 2016; van Wegberg et al., 2017), Phe levels often carry strong emotional meaning.
It can help to remember that lab results are information. They guide care. They are not judgments. Building in an adjustment period, emotionally as well as medically, can ease this transition.
Planning for Either Outcome
Before beginning a new therapy, open conversations with your metabolic team can reduce uncertainty. Consider discussing:
· What defines success?
· How long will we trial the treatment?
· What happens if Phe levels do not improve enough?
· How will diet be adjusted if levels improve?
Preparing for multiple possible outcomes makes the process feel less like a single high-stakes decision and more like an informed, stepwise approach.
Moving Forward
PKU care continues to evolve because science continues to advance. New treatments aim not only to improve metabolic control but also to enhance overall quality of life (van Wegberg et al., 2017). Whether a new treatment leads to significant change, partial benefit, or a return to previous strategies, each step adds knowledge and clarity. PKU management is rarely a straight line. It is a long-term partnership with science, with healthcare providers, and within families.
Change can feel challenging. It can also be empowering. Wherever the path leads, you are not navigating it alone.
For those who would like additional guidance or support, connecting with a mental health professional can be helpful. Please visit: Psychology Today (www.psychologytoday.com) to search for a therapist based on your preferences (e.g., gender of therapist, insurance accepted, areas of expertise, and location).
References
Bilder, D. A., Burton, B. K., Coon, H., et al. (2016). Neuropsychiatric comorbidities in adults with phenylketonuria: A retrospective cohort study. Molecular Genetics and Metabolism, 118(3), 155–160. https://doi.org/10.1016/j.ymgme.2016.05.007
Burton, B. K., Grange, D. K., Milanowski, A., et al. (2015). The use of sapropterin dihydrochloride in phenylketonuria: Results of a phase III, randomized, placebo-controlled trial. Molecular Genetics and Metabolism, 114(2), 116–123.
Ford, S., O’Driscoll, M., & MacDonald, A. (2018). Living with phenylketonuria: Lessons from the PKU community. Molecular Genetics and Metabolism Reports, 17, 57–63.
Longo, N., Harding, C. O., Burton, B. K., et al. (2019). Single-dose, randomized, controlled trials of pegvaliase in adults with phenylketonuria. The Lancet, 394(10198), 1467–1476.
van Wegberg, A. M. J., MacDonald, A., Ahring, K., et al. (2017). The complete European guidelines on phenylketonuria: Diagnosis and treatment. Orphanet Journal of Rare Diseases, 12, 162. https://doi.org/10.1186/s13023-017-0685-2